Picard Advances Patent Protection for Fully Implantable Artificial Heart Technology
Picard Medical (NYSE American: PMI) has strengthened its intellectual property portfolio with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation SynCardia Total Artificial Heart (STAH), dubbed the "Emperor." The company now holds 34 patented claims across three U.S. patents and has secured protection in China through Patent No. 115279450 B.
The Emperor represents a significant advancement as a fully implantable artificial heart that provides pulsatile flow without requiring an external pneumatic driver. This technology aims to revolutionize treatment options for end-stage heart failure patients, offering enhanced patient flexibility and improved quality of life.
Picard Medical (NYSE American: PMI) ha rafforzato il proprio portafoglio di proprietà intellettuale con l'ottenimento della US Patent No. 12,383,722 B2 per il suo cuore artificiale totale di nuova generazione SynCardia (STAH), soprannominato “Emperor.” L'azienda detiene ora 34 rivendicazioni brevettuali tra tre brevetti statunitensi e ha ottenuto protezione in Cina tramite la patente No. 115279450 B. L'Emperor rappresenta un progresso significativo in quanto cuore artificiale completamente impiantabile che fornisce flusso pulsatile senza necessità di un driver pneumatico esterno. Questa tecnologia punta a rivoluzionare le opzioni di trattamento per i pazienti con insufficienza cardiaca terminale, offrendo una maggiore flessibilità ai pazienti e una migliore qualità della vita.
Picard Medical (NYSE American: PMI) ha fortalecido su cartera de propiedad intelectual con la concesión de la Patente de EE. UU. No. 12,383,722 B2 para su corazón artificial total de próxima generación SynCardia (STAH), apodado “Emperor.” La compañía ahora posee 34 reivindicaciones patentables entre tres patentes estadounidenses y ha asegurado protección en China mediante la patente No. 115279450 B. El Emperor representa un avance significativo como corazón artificial totalmente implantable que proporciona un flujo pulsátil sin necesidad de un controlador neumático externo. Esta tecnología tiene como objetivo revolucionar las opciones de tratamiento para pacientes con insuficiencia cardíaca en fase terminal, ofreciendo mayor flexibilidad al paciente y una mejor calidad de vida.
Picard Medical (NYSE American: PMI)은 STAH로 불리는 차세대 SynCardia Total Artificial Heart의 미국 특허번호 12,383,722 B2 부여로 지적 재산 포트폴리오를 강화했습니다. 이 회사는 이제 34개의 특허 청구항을 보유하고 있으며, 미국의 세 가지 특허에 걸쳐 보호를 받으며 중국에서도 특허번호 115279450 B를 통해 보호를 확보했습니다. Emperor는 외부 공압 구동기가 필요 없이 펄스형 혈류를 제공하는 완전 이식 가능 인공심장으로서 상당한 발전을 나타냅니다. 이 기술은 말기 심부전 환자에 대한 치료 옵션을 혁신하는 것을 목표로 하며, 환자 유연성과 삶의 질을 향상시키는 것을 약속합니다.
Picard Medical (NYSE American: PMI) a renforcé son portefeuille de propriété intellectuelle avec l'octroi du brevet américain n° 12,383,722 B2 pour son cœur artificiel total de prochaine génération SynCardia (STAH), surnommé « Emperor ». L'entreprise détient désormais 34 revendications brevetables réparties sur trois brevets américains et a obtenu une protection en Chine par le brevet n° 115279450 B. L'Emperor représente une avancée majeure en tant que cœur artificiel entièrement implantable qui fournit un flux pulsatile sans nécessiter de driver pneumatique externe. Cette technologie vise à révolutionner les options de traitement pour les patients atteints d'insuffisance cardiaque terminale, offrant une plus grande flexibilité pour les patients et une meilleure qualité de vie.
Picard Medical (NYSE American: PMI) hat sein Portfolio an geistigem Eigentum durch die Erteilung des US-Patents Nr. 12,383,722 B2 für ihr nächstgeneration SynCardia Total Artificial Heart (STAH) namens „Emperor“ gestärkt. Das Unternehmen hält nun 34 patentierte Ansprüche über drei US-Patente und hat auch in China durch das Patent Nr. 115279450 B Schutz erhalten. Der Emperor stellt eine bedeutende Fortentwicklung dar, da es sich um ein vollständig implantierbares künstliches Herz handelt, das einen pulsierenden Fluss liefert, ohne dass ein externes pneumatisches Treibermodul erforderlich ist. Diese Technologie zielt darauf ab, die Behandlungsoptionen für Patienten mit Endstadium der Herzinsuffizienz zu revolutionieren und bietet dem Patienten mehr Flexibilität sowie eine verbesserte Lebensqualität.
Picard Medical (NYSE American: PMI) قد عززت شركة Picard Medical محفظة ملكيتها الفكرية بمنحها براءة الاختراع الأمريكية رقم 12,383,722 B2 لقلوب SynCardia الاصطناعية الكلية من الجيل التالي (STAH)، الملقب بـ“Emperor”. تمتلك الشركة الآن 34 طلباً برائياً عبر ثلاث براءات أميركية، وحصلت على حماية في الصين من خلال براءة رقم 115279450 B. يمثل Emperor تقدماً هاماً كـ قلب اصطناعي قابل للزراعة بالكامل لا يحتاج إلى محرك هوائي خارجي، ويوفر تدفقاً نابضاً. تهدف هذه التقنية إلى إحداث ثورة في خيارات العلاج للمرضى المصابين بفشل القلب في مراحله النهائية، مع توفير مرونة أكبر للمرضى وتحسين جودة الحياة.
Picard Medical (NYSE American: PMI) 通过获得用于其下一代 SynCardia 全人工心脏（STAH）“Emperor”的美国专利号 12,383,722 B2，进一步强化了其知识产权组合。公司现拥有三项美国专利下的 34 项专利权利要求，并已通过专利号 115279450 B 获得在中国的保护。Emperor 代表着一项重要进展，因为它是一种 完全可移植的人工心脏，无需外部气动驱动器即可提供搏动性血流。该技术旨在为末期心力衰竭患者的治疗选择带来变革，为患者提供更高的灵活性和更好的生活质量。
- None.
- None.
Insights
Picard strengthens patent portfolio for its implantable artificial heart, securing competitive advantage in a valuable medical device market.
Picard Medical has significantly enhanced its intellectual property position with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation fully implantable artificial heart technology, the "Emperor." This patent, alongside two previously secured U.S. patents and one Chinese patent, brings their protected claims to 34 in the United States alone. This strategic IP expansion creates substantial barriers to entry for competitors in the artificial heart space.
The Emperor technology represents a notable advancement over current artificial heart systems, as it eliminates the need for external pneumatic drivers while maintaining pulsatile flow. For medical device companies, robust patent protection is critical for market exclusivity and typically translates to premium pricing power and stronger market positioning during the patent life.
The company's decision to extend patent protection into China is particularly strategic, given China's growing medical device market and increasing prevalence of cardiovascular disease. By securing international IP rights, Picard is positioning itself for global commercialization pathways rather than limiting its market potential to North America.
From a competitive standpoint, these patents could provide Picard with a 10-20 year exclusivity window for its technology, depending on patent filing dates. This exclusivity period is especially valuable in medical devices where development cycles are lengthy and regulatory hurdles are substantial. The company appears to be building a comprehensive patent thicket around its technology, which typically makes it more difficult for competitors to engineer around their protected innovations.
- Patent portfolio secures innovation for the future of heart replacement -
TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the strengthening of its intellectual property portfolio with the recent grant of U.S. Patent No. 12,383,722 B2 covering systems and methods related to its next-generation SynCardia Total Artificial Heart (STAH), the “Emperor.”
This recently granted patent, relating to the apparatus, systems, and methods for enabling a next-generation total artificial heart which provides enhanced patient flexibility, builds on earlier grants U.S. Patent No. 11,918,798 B2 and U.S. Patent No. 12,121,711 B2, bringing the Company’s total number of patented claims in the United States to 34 covering its next-generation total artificial heart system. In addition, the Company holds China Patent No. 115279450 B, which extends similar protection for the fully implantable platform in that jurisdiction. The Emperor is expected to be fully implantable and provide pulsatile flow without requiring an external pneumatic driver.
“Our growing patent portfolio underscores SynCardia’s commitment to advancing our life-saving technology,” said Matt Schuster, COO of SynCardia. “The Emperor represents the future of treatment for end-stage heart failure patients. By securing 34 claims across three U.S. patents and extending protection into China, we have created a strong international foundation around our next-generation platform. Securing this patent marks an important milestone in protecting the innovation behind our fully implantable artificial heart and supports our goal for long-term market growth driven by IP-backed innovation.”
The Company expects to continue expanding its portfolio globally to safeguard the durable and efficient mechanisms, advanced electronics, long-term durability, operational efficiency, and wireless implantable features that define its next-generation platform.
“We are building the foundation for SynCardia’s future by developing the world’s first fully implantable, durable, and patient-friendly total artificial heart,” said Patrick NJ Schnegelsberg, CEO of SynCardia. “Our patent portfolio secures the path from development to commercialization and positions us to help shape the future of heart replacement worldwide.”
“We are building the foundation for SynCardia’s future by developing the world’s first fully implantable, durable, and patient-friendly total artificial heart,” said Patrick NJ Schnegelsberg, CEO of SynCardia. “Our patent portfolio secures the path from development to commercialization and ensures long-term global leadership.”
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
Picard Medical, Inc./SynCardia Systems, LLC
General/Media
Brittany Lanza
FAQ
What is the significance of Picard Medical's new patent for the Emperor artificial heart?
How many patents does Picard Medical (PMI) now hold for its artificial heart technology?
What are the key features of Picard Medical's Emperor artificial heart?
How does the Emperor artificial heart differ from current artificial heart technology?
What markets are covered by Picard Medical's artificial heart patents?
